Angiotech

(ANPI)

said

Nestle's

(NSRGY)

Alcan unit ended plans to jointly develop implants for various eye diseases.

The biotech company said the collaboration's lead product had failed to meet performance criteria sufficient to further develop it.

The companies entered an exclusive, worldwide agreement to research the implants in May 2000.